A One Year, Open-Label Outpatient, Parallel Group Trial Assessing the Impact of the Availability of Inhaled Insulin (Exubera) on Glycemic Control in Patients With Type 2 Diabetes Mellitus Who Are Poorly Controlled on a Minimum of Two Oral Anti Diabetic Agents

Trial Profile

A One Year, Open-Label Outpatient, Parallel Group Trial Assessing the Impact of the Availability of Inhaled Insulin (Exubera) on Glycemic Control in Patients With Type 2 Diabetes Mellitus Who Are Poorly Controlled on a Minimum of Two Oral Anti Diabetic Agents

Completed
Phase of Trial: Phase III

Latest Information Update: 29 Jun 2013

At a glance

  • Drugs Insulin (Primary) ; Antihyperglycaemics; Insulin
  • Indications Type 2 diabetes mellitus
  • Focus Pharmacogenomic; Registrational; Therapeutic Use
  • Acronyms EXPERIENCE
  • Sponsors Pfizer
  • Most Recent Events

    • 01 Jun 2008 The primary endpoint has been 'Met' (Proportion of glycosylated haemoglobin) according to the Preliminary results reported in Diabetic Medicine.
    • 13 Jul 2007 Status changed from recruiting to in progress.
    • 26 Nov 2005 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top